Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Watkinson A, Soliakov A, Ganesan A, Hirst K, Lebutt C, Fleetwood K, Fusco PC, Fuerst TR, Lakey JH.

Clin Vaccine Immunol. 2013 Nov;20(11):1659-68. doi: 10.1128/CVI.00320-13. Epub 2013 Aug 28.

2.

Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.

Jendrek S, Little SF, Hem S, Mitra G, Giardina S.

Vaccine. 2003 Jun 20;21(21-22):3011-8.

PMID:
12798645
3.

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

Berthold I, Pombo ML, Wagner L, Arciniega JL.

Vaccine. 2005 Mar 14;23(16):1993-9.

PMID:
15734073
4.

Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL.

Clin Vaccine Immunol. 2012 Sep;19(9):1465-73. doi: 10.1128/CVI.00174-12. Epub 2012 Jul 18.

5.

Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.

Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP.

Vaccine. 2007 Apr 12;25(15):2771-7. Epub 2007 Jan 2.

PMID:
17240008
6.

Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.

Iyer V, Hu L, Schanté CE, Vance D, Chadwick C, Jain NK, Brey RN, Joshi SB, Volkin DB, Andra KK, Bann JG, Mantis NJ, Middaugh CR.

Hum Vaccin Immunother. 2013 Nov;9(11):2362-70. Epub 2013 Aug 7.

7.

Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles.

Li X, Aldayel AM, Cui Z.

J Control Release. 2014 Jan 10;173:148-57. doi: 10.1016/j.jconrel.2013.10.032. Epub 2013 Nov 1.

8.

Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Oscherwitz J, Feldman D, Yu F, Cease KB.

Vaccine. 2015 Jan 9;33(3):430-6. doi: 10.1016/j.vaccine.2014.11.042. Epub 2014 Nov 30.

9.

Stable dry powder formulation for nasal delivery of anthrax vaccine.

Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ.

J Pharm Sci. 2012 Jan;101(1):31-47. doi: 10.1002/jps.22742. Epub 2011 Sep 8.

10.

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP.

Vaccine. 2004 Jan 2;22(3-4):422-30.

PMID:
14670324
11.

Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine.

D'Souza AJ, Mar KD, Huang J, Majumdar S, Ford BM, Dyas B, Ulrich RG, Sullivan VJ.

J Pharm Sci. 2013 Feb;102(2):454-61. doi: 10.1002/jps.23422. Epub 2012 Dec 14.

PMID:
23242822
12.

Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.

Domínguez-Castillo RI, Verma A, Amador-Molina JC, Sirota L, Arciniega JL.

Biologicals. 2013 Mar;41(2):111-4. doi: 10.1016/j.biologicals.2012.10.002. Epub 2012 Nov 6.

PMID:
23137818
13.

Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.

Bento D, Staats HF, Gonçalves T, Borges O.

Eur J Pharm Biopharm. 2015 Jun;93:149-64. doi: 10.1016/j.ejpb.2015.03.024. Epub 2015 Mar 26.

PMID:
25818119
14.

Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants.

Ljutic B, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF.

Vaccine. 2012 Apr 19;30(19):2981-8. doi: 10.1016/j.vaccine.2012.02.038. Epub 2012 Feb 27.

PMID:
22381074
15.

Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Soliakov A, Kelly IF, Lakey JH, Watkinson A.

Eur J Pharm Biopharm. 2012 Jan;80(1):25-32. doi: 10.1016/j.ejpb.2011.09.009. Epub 2011 Sep 22.

16.

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.

Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR.

J Immunol. 2003 Jun 1;170(11):5636-43.

18.

Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Rao M, Peachman KK, Li Q, Matyas GR, Shivachandra SB, Borschel R, Morthole VI, Fernandez-Prada C, Alving CR, Rao VB.

Vaccine. 2011 Jan 29;29(5):873-7. doi: 10.1016/j.vaccine.2010.11.049. Epub 2010 Nov 27.

19.

Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.

Lynch HE, Stewart SM, Kepler TB, Sempowski GD, Alam SM.

J Immunol Methods. 2014 Feb;404:1-12. doi: 10.1016/j.jim.2013.11.026. Epub 2013 Dec 4.

20.

Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.

Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP.

Vaccine. 2006 Apr 24;24(17):3469-76. Epub 2006 Feb 21.

PMID:
16519970

Supplemental Content

Support Center